Sol-Gel Technologies Ltd.

Healthcare · Biotechnology · Israel

Last price 68.59 USD (Oct 30, 2026, 3:02 PM EDT) · Market cap 224.56M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-...